Conclusions from the HIV in Europe Copenhagen 2012 Conference and ways forward: Working together for optimal HIV testing and earlier care

HIV Medicine

Volumn 14, Issue SUPPL.3, 2013, Pages 1-5

  Raben, D ^a   Delpech, V ^b   de Wit, J ^c   Sullivan, A ^d   Lazarus, Jv ^a   Dedes, N ^e   Coenen, T ^f   Lundgren, J ^a,g  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e EUROPEAN AIDS TREATMENT GROUP   (Belgium)

^f Health Action International Europe   (Netherlands)

^g University of Copenhagen   (Denmark)

Author keywords

HIV care; HIV testing; Late diagnosis

Indexed keywords

ARTICLE; COUNSELING; EUROPE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEPATITIS; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; PATIENT CARE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION;

HIV CARE; HIV TESTING; LATE DIAGNOSIS;

CONGRESSES AS TOPIC; DELAYED DIAGNOSIS; DENMARK; EUROPE; HEPATITIS; HIV; HIV SEROPOSITIVITY; HUMANS; MASS SCREENING;

EID: 84883427758     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12062     Document Type: Article

References (23)

1. European Centre for Disease Prevention and Control. 2012) HIV/AIDS surveillance in Europe 2011 report. Available at http://ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=1009 (accessed 21 May 2013).
2. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med 2008; 9 (Suppl 2): S6-12.
3. Nakagawa F, Lodwick RK, Smith CJ etal. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-343.
4. Wilson DP, Hoare A, Regan DG, Law MG. Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. Sex Health 2009; 6: 19-33.
5. Egger M, May M, Chêne G etal. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
6. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20: 1447-1450.
7. Fleishman JA, Yehia BR, Moore RD, Gebo KA, HIV Research Network. The economic burden of late entry into medical care for patients with HIV infection. Med Care 2010; 48: 1071-1079.
8. Branson BM, Handsfield HH, Lampe MA etal. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006; 55 (RR14): 1-17.
9. Palfreeman A, Fisher M, Ong E etal. Testing for HIV: concise guidance. Clin Med 2009; 9: 471-476.
10. WHO & UNAIDS. Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities. Geneva, WHO, UNAIDS, 2007.
11. British HIV Association, British Association of Sexual Health and HIV, British Infection Society. 2008) UK national guidelines for HIV testing 2008. Available at http://www.bhiva.org/HIVTesting2008.aspx (accessed 25 April 2012).
12. European Centre for Disease Prevention and Control. 2010) ECDC guidance. HIV testing: increasing uptake and effectiveness in the European Union. Available at http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=588 (accessed 25 April 2012).
13. HIV in Europe, HIV indicator conditions: guidance for implementing HIV testing in adults in health care settings. October 2012. Available at http://www.hiveurope.eu (accessed 5 November 2012).
14. Lazarus JV, Hoekstra M, Raben D, Delpech V, Coenen T and Lundgren JD. The case for indicator condition-guided HIV screening HIV Medicine HIV in Europe Initiative Steering Committee. Article first published online: 10 Mar 2013. doi: 10.1111/hiv.12022.
15. Sullivan A, Raben D, Reekie J, Rayment M, Mocroft A. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES 1. PLoS ONE 2013; 8: e52845.
16. Yazdanpanah Y, Sloan CE, Charlois-Ou C etal. Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS ONE 2010; 5: e13132.
17. Gazzard B, Clumeck N, D'Arminio Monforte A, Lundgren JD. Indicator diseases-guided testing for HIV - the next step for Europe? HIV Med 2008; 9 (Suppl 2): 34-40.
18. Paltiel AD, Weinstein MC, Kimmel AD etal. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med 2005; 352: 586-595.
19. Sanders GD, Bayoumi AM, Sundaram V etal. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352: 570-585.
20. Rayment M, Thornton A, Mandalia S etal. HIV testing in non-traditional settings - the HINTS Study: a Multi-Centre Observational Study of Feasibility and Acceptability. PLoS ONE 2012; 7: e39530. doi:10.1371/journal.pone.0039530.
21. Thornton A, Rayment M, Elam G etal. Exploring staff attitudes to routine HIV testing in non-traditional settings: a qualitative study in four healthcare facilities. Sex Transm Infect 2012; 88: 601-606. doi:10.1136/sextrans-2012-050584.
22. Antinori A, Coenen T, Costagiola D etal. for the European Late Presenter Consensus working group. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 61-64.
23. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800.